ConductScience.org, home

Trial · NCT00833248

Participant flow12

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDDegarelix 240 mg/80 mg181
Overall StudySTARTEDGoserelin (3.6 mg) + Bicalutamide (50 mg)65
Overall StudyFull Analysis Set (FAS)Degarelix 240 mg/80 mg180
Overall StudyFull Analysis Set (FAS)Goserelin (3.6 mg) + Bicalutamide (50 mg)64
Overall StudyPer Protocol (PP) Analysis SetDegarelix 240 mg/80 mg164
Overall StudyPer Protocol (PP) Analysis SetGoserelin (3.6 mg) + Bicalutamide (50 mg)57
Overall StudySafety Analysis SetDegarelix 240 mg/80 mg181
Overall StudySafety Analysis SetGoserelin (3.6 mg) + Bicalutamide (50 mg)64
Overall StudyCOMPLETEDDegarelix 240 mg/80 mg177
Overall StudyCOMPLETEDGoserelin (3.6 mg) + Bicalutamide (50 mg)62
Overall StudyNOT COMPLETEDDegarelix 240 mg/80 mg4
Overall StudyNOT COMPLETEDGoserelin (3.6 mg) + Bicalutamide (50 mg)3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00833248/flow